Principal Investigator
Macarena De La Fuente
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20240880
Clinical Trial Summary
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Neurological Cancer
Contact Information
Phone Number
305-243-2647